Jingyi Huang

Jingyi Huang

Auto-generated profile, based on publicly available information

Jingyi Huang

School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, China; Academy of Chinese Medical Science, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2024 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
HZHongyan Zhang
Hongyan Zhang
YLYuJie Li
YuJie Li
JHJingyi Huang
Jingyi Huang
LSLimei Shen
Limei Shen
XYXiong Yang
Xiong Yang
Over the past decade, research has increasingly identified unique dysregulations in lipid metabolism within the tumor microenvironment (TME). Lipids, diverse biomolecules, not only constitute biological membranes but also function as signaling molecules and energy sources. Enhanced synthesis or uptake of lipids in the TME significantly promotes tumorigenesis and proliferation. Moreover, lipids secreted into the TME influence tumor-resident immune cells (TRICs), thereby aiding tumor survival against chemotherapy and immunotherapy. This review aims to highlight recent advancements in understanding lipid metabolism in both tumor cells and TRICs, with a particular emphasis on exogenous lipid uptake and endogenous lipid de novo synthesis. Targeting lipid metabolism for intervention in anticancer therapies offers a promising therapeutic avenue for cancer treatment. Nano-drug delivery systems (NDDSs) have emerged as a means to maximize anti-tumor effects by rewiring tumor metabolism. This review provides a comprehensive overview of recent literature on the development of NDDSs targeting tumor lipid metabolism, particularly in the context of tumor immunotherapy. It covers four key aspects: reprogramming lipid uptake, reprogramming lipolysis, reshaping fatty acid oxidation (FAO), and reshuffling lipid composition on the cell membrane. The review concludes with a discussion of future prospects and challenges in this burgeoning field of research.

21 August 2023 in Osteoarthritis and Cartilage
Verified
Journal Article
Open access
MLMing Liu
Ming Liu
NHNafiza Haque
Nafiza Haque
JHJingyi Huang
Jingyi Huang
GZGuangju Zhai
Guangju Zhai
To highlight the advances over the past year in metabolite/protein biomarkers for osteoarthritis (OA). A literature search of five databases including PubMed, Web of Science, Scopus, Ovid Medline, and Embase was performed for studies on metabolite/protein/peptide/biochemical markers for OA published between April 01, 2022 and March 31, 2023. Records were then screened to include only original research articles using directly collected human specimen, in English language, and with full text available. Data from eligible studies were systematically extracted and summarized. A total of 1,600 unique records were extracted, out of which 46 fulfilled the inclusion criteria and were used for data extraction. Forty-one of these 46 studies focused on biomarkers for OA/OA severity/progression, four on OA clustering, and one on OA treatment outcomes. Twenty-nine studied protein markers for OA, thirteen studied metabolite markers, and four studied both. While many studies were the validation of the previously reported biomarkers, a number of novel metabolite/protein biomarkers and biomarker panels were reported in the past year. Biomarker panels might be useful to subset OA patients. The number of studies on OA clustering is rising. Although validation in larger cohorts is needed in order to utilize reported biomarkers in clinical practice, these discoveries help better understand the pathogenesis of OA, provide insights into possible mechanisms underlying poor treatment outcomes, and aid in developing personalized treatment based on OA subtypes.

18 January 2024 in JMIR Public Health and Surveillance
Verified
Journal Article
Open access
XRXiaohao Ruan
Xiaohao Ruan
NZNing Zhang
Ning Zhang
DWDawei Wang
Dawei Wang
JHJingyi Huang
Jingyi Huang
JHJinlun Huang
Jinlun Huang
Rong NaRong Na
Rong Na
Background: The status of prostate-specific antigen (PSA) screening is unclear in China. Evidence regarding the optimal frequency and interval of serial screening for prostate cancer (PCa) is disputable. Objective: This study aimed to depict the status of PSA screening and to explore the optimal screening frequency for PCa in China. Methods: A 13-year prospective cohort study was conducted using the Chinese Electronic Health Records Research in Yinzhou study’s data set. A total of 420,941 male participants aged ≥45 years were included between January 2009 and June 2022. Diagnosis of PCa, cancer-specific death, and all-cause death were obtained from the electronic health records and vital statistic system. Hazard ratios (HRs) with 95% CIs were estimated using Cox regression analysis. Results: The cumulative rate of ever PSA testing was 17.9% with an average annual percent change (AAPC) of 8.7% (95% CI 3.6%-14.0%) in the past decade in China. People with an older age, a higher BMI, higher waist circumference, tobacco smoking and alcohol drinking behaviors, higher level of physical activity, medication use, and comorbidities were more likely to receive PSA screening, whereas those with a lower education level and a widowed status were less likely to receive the test. People receiving serial screening ≥3 times were at a 67% higher risk of PCa detection (HR 1.67; 95% CI 1.48-1.88) but a 64% lower risk of PCa-specific mortality (HR 0.36; 95% CI 0.18-0.70) and a 28% lower risk of overall mortality (HR 0.72; 95% CI 0.67-0.77). People following a serial screening strategy at least once every 4 years were at a 25% higher risk of PCa detection (HR 1.25; 95% CI 1.13-1.36) but 70% (HR 0.30; 95% CI 0.16-0.57) and 23% (HR 0.77; 95% CI 0.73-0.82) lower risks of PCa-specific and all-cause mortality, respectively. Conclusions: This study reveals a low coverage of PSA screening in China and provides the first evidence of its benefits in the general Chinese population. The findings of this study indicate that receiving serial screening at least once every 4 years is beneficial for overall and PCa-specific survival. Further studies based on a nationwide population and with long-term follow-up are warranted to identify the optimal screening interval in China.

25 August 2024 in International Immunopharmacology
Verified
Journal Article
Closed access
JHJingyi Huang
Jingyi Huang
HZHongyan Zhang
Hongyan Zhang
LMLisha Ma
Lisha Ma
NMNinghui Ma
Ninghui Ma
NLNingchao Luo
Ningchao Luo
YXYang Xiong
Yang Xiong

19 October 2023 in Cambridge Prisms: Precision Medicine
Verified
Journal Article
Open access
PDF file
JHJingyi Huang
Jingyi Huang
DHDa Huang
Da Huang
XRXiaohao Ruan
Xiaohao Ruan
YZYongle Zhan
Yongle Zhan
SCStacia T.-T. Chun
Stacia T.-T. Chun
Rong NaRong Na
Rong Na
The aim of liquid biopsies is to obtain tumor information via the molecular interrogation of liquid samples, including blood and urine. As a minimally invasive procedure, liquid biopsies have attracted attention. A series of studies have reported associations of biomarkers such as circulating tumor DNA, cell-free DNA and extracellular vesicles with urological cancers, especially prostate cancer (PCa), and demonstrated the promising potential of liquid biopsies. In this review, we summarize recent clinical translational studies of liquid biopsies in PCa and other urological cancers, including bladder cancer and renal cell carcinoma. The number of translational studies was limited, and most of the studies focused on PCa. Biomarkers isolated from blood by different detection methods could be applied in clinical practice to predict prognosis and treatment response in advanced PCa. The other applications in urological cancers identified in previous studies remain to be explored further. Current studies are limited due to the lack of ideal standard detection methods for biomarkers. In the future, with advances in methodology, more translational studies will be conducted to identify potential applications of liquid biopsies in urological cancers.

2 February 2023 in Cancer Medicine
Verified
Journal Article
Open access
DHDa Huang
Da Huang
XRXiaohao Ruan
Xiaohao Ruan
JHJingyi Huang
Jingyi Huang
NZNing Zhang
Ning Zhang
GJGuangliang Jiang
Guangliang Jiang
Rong NaRong Na
Rong Na
Background: Active surveillance/watchful waiting (AS/WW) is feasible and effective for favorable‐risk prostate cancer (PCa). Understanding socioeconomic determinants of AS/WW may help determine the target population for social support and improve cancer‐related survival.Methods: The Surveillance, Epidemiology, and End Results Prostate with Watchful Waiting Database 18 Registries identified 229,428 adult men diagnosed with primary localized PCa (clinical T1‐T2c, N0M0) during a median follow‐up of 45 months between 2010 and 2016. Socioeconomic determinants included socioeconomic status (SES) tertiles, marital status (unmarried vs married), and residency (urban vs rural). Multivariable logistic regression and Cox models determined the adjusted odds ratios (aOR) for AS/WW utilization, and adjusted hazard ratio (aHR) for cancer‐specific survival (CSS) and overall survival (OS). The extent of missing data was evaluated by multiple imputation. Sensitivity analyses were performed in multiple imputation datasets.Results: Unmarried patients were more likely to receive AS/WW in low‐risk group (aOR, 1.20 [95%CI, 1.12–1.28]; p < 0.001) and favorable intermediate‐risk group (aOR, 1.41 [95%CI, 1.26–1.59]; p < 0.001) than married patients. Urban patients had 0.77‐fold lower likelihood of AS/WW than rural patients in low‐risk group (95% CI, 0.68–0.87; p < 0.001), but not in favorable intermediate‐risk groups. Among patients undertaking AS/WW, a significantly worse OS was observed among unmarried patients comparing to married group (aHR, 1.98 [95% CI, 1.50–2.60]; p < 0.001), and patients with high SES had better CSS than low group (aHR, 0.08 [95%CI, 0.01–0.69]; p = 0.02). No significant survival difference was found between urban and rural patients.Conclusions and Relevance: Unmarried or urban patients had significantly higher rates of AS/WW. The utilization and efficacy of conservative management were affected by socioeconomic factors, which might serve as a barrier of treatment decision‐making and targeted a population in need of social support.